1. Home
  2. VTAK vs JAGX Comparison

VTAK vs JAGX Comparison

Compare VTAK & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTAK
  • JAGX
  • Stock Information
  • Founded
  • VTAK 2002
  • JAGX 2013
  • Country
  • VTAK United States
  • JAGX United States
  • Employees
  • VTAK N/A
  • JAGX N/A
  • Industry
  • VTAK Medical/Dental Instruments
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VTAK Health Care
  • JAGX Health Care
  • Exchange
  • VTAK Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • VTAK 3.1M
  • JAGX 3.5M
  • IPO Year
  • VTAK 2018
  • JAGX N/A
  • Fundamental
  • Price
  • VTAK $0.24
  • JAGX $2.63
  • Analyst Decision
  • VTAK
  • JAGX Strong Buy
  • Analyst Count
  • VTAK 0
  • JAGX 1
  • Target Price
  • VTAK N/A
  • JAGX $60.00
  • AVG Volume (30 Days)
  • VTAK 41.3M
  • JAGX 80.9K
  • Earning Date
  • VTAK 08-13-2025
  • JAGX 08-12-2025
  • Dividend Yield
  • VTAK N/A
  • JAGX N/A
  • EPS Growth
  • VTAK N/A
  • JAGX N/A
  • EPS
  • VTAK N/A
  • JAGX N/A
  • Revenue
  • VTAK $481,000.00
  • JAGX $11,552,000.00
  • Revenue This Year
  • VTAK $822.86
  • JAGX $22.41
  • Revenue Next Year
  • VTAK $168.42
  • JAGX $30.00
  • P/E Ratio
  • VTAK N/A
  • JAGX N/A
  • Revenue Growth
  • VTAK 9.57
  • JAGX 13.93
  • 52 Week Low
  • VTAK $0.16
  • JAGX $2.43
  • 52 Week High
  • VTAK $4.76
  • JAGX $110.75
  • Technical
  • Relative Strength Index (RSI)
  • VTAK 45.34
  • JAGX 31.41
  • Support Level
  • VTAK $0.22
  • JAGX $2.53
  • Resistance Level
  • VTAK $0.25
  • JAGX $2.65
  • Average True Range (ATR)
  • VTAK 0.02
  • JAGX 0.21
  • MACD
  • VTAK -0.01
  • JAGX 0.12
  • Stochastic Oscillator
  • VTAK 11.79
  • JAGX 22.99

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: